Howard M. Sandler, MD

Howard M. Sandler, MD, chair, Department of Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, director, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses hypofractionation in prostate cancer.

Howard M. Sandler, MD, chair, Department of Radiation Oncology, professor of Radiation Oncology, Cedars-Sinai Medical Center, discusses potential combination regimens with chemotherapy as treatment for patients with prostate cancer.

Howard M. Sandler, MD, discusses the RTOG 94-06 study, which analyzed three dimensional conformal radiation therapy and intensity-modulated radiation therapy (IMRT) for patients with prostate cancer.

Howard M. Sandler, MD, from the Cedars-Sinai Medical Center, describes his excitement over research into new agents that modulate the androgen axis in prostate cancer.

Howard M. Sandler, MD, the Chair of Radiation Oncology at Cedars-Sinai Medical Center, discusses radium-223, a novel alpha radiation emitting agent under evaluation by the FDA for patients with bone metastases from advanced castration-resistant prostate cancer (CRPC).

Dr. Howard Sandler, from Cedars-Sinai Medical Center, Describes the RTOG 9408 Prostate Cancer Trial Results

Dr. Howard Sandler from Cedars-Sinai Medical Center discusses the TAK-700 in Localized Prostate Cancer Clinical Trials

Howard M. Sandler, MD, MS from Cedars-Sinai Medical Center, on Guideline Compliant Care

Howard M. Sandler, MD, MS, from Cedars-Sinai Medical Center, discusses candidates for liase inhibitor clinical trials.

Howard M. Sandler, MD, MS, from Cedars-Sinai Medical Center, compares the efficacy of the mechanism of action for traditional LHRH agonists to newer androgen deprivation therapies